微創醫療(00853.HK)斥逾3.7億人幣參投OCT系統解決方案供應商
微創醫療(00853.HK)公布,斥3.723億元人民幣,購入阿格斯38.33%的權益及向阿格斯新增註冊資本。
完成後,集團將持有阿格斯51%股權。
阿格斯成立於2016年,其主營業務包括設計、開發以及銷售用於血管內光學干涉斷層成像(OCT)系統的解決方案,目前已成功自主研發了ArgusClarity OCT系統及Argus NOPURGETM全封閉式免沖洗一次性成像導管。
公司稱,是次戰略合作將會進一步完善集團在泛血管領域的一體化精準診療解決方案,屬其在冠心病
治療全解醫療方案領域的重要佈局,同時也將促進阿格斯的OCT系統及其免沖洗一次性成像導管的市場拓展,從而為心血管醫生提供更精準的醫療手段,讓更多冠心病患者受益於前沿醫療科技。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.